MESO

Business Context and Reporting Period

Company: Mesoblast Limited (ASX: MESO, NASDAQ: MESO)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Six months ended December 31, 2025
Business Overview: Mesoblast is a biopharmaceutical company developing allogeneic cellular medicines for inflammatory conditions. The period marks the first six months of commercial sales for its FDA-approved product, Ryoncil® (remestemcel-L), indicated for pediatric steroid-refractory acute graft-versus-host disease (SR-aGVHD), which launched in the U.S. in March 2025.

Key Financial Metrics

Note: Net Debt calculation includes borrowings, lease liabilities, and warrant liabilities offset by cash. The 2025 period reflects a shift to a net cash position due to new financing.

Material Changes vs. Prior Period

• Revenue Surge: Total revenue increased by $48.2 million (1,527%) driven entirely by the commercial launch of Ryoncil, generating $48.7 million in net product sales. Royalty revenue declined slightly by $0.5 million.
• Expense Reclassification: The company retrospectively reclassified expenses to better reflect commercialization. Manufacturing and commercialization costs for Ryoncil were moved from R&D to Cost of Revenues and SG&A, respectively. This resulted in a reported R&D expense of $46.2 million (up from $5.1 million previously reported) and SG&A of $28.5 million (up from $18.0 million).
• Debt Restructuring: In December 2025, the company entered a new $125.0 million five-year credit-line facility. It drew $75.0 million to fully repay its senior secured loan with Oaktree Capital Management and partially repay its NovaQuest facility. This reduced interest costs and improved liquidity.
• Non-Cash Gains/Losses: A $7.6 million gain was recognized from the remeasurement of contingent consideration (primarily due to share price movements on a milestone payment). Conversely, a $4.5 million loss was recorded on the remeasurement of warrant liabilities.

Guidance, Outlook, and Risks

Outlook and Liquidity: Management expects existing cash reserves ($130.0 million) combined with Ryoncil sales to fund operations for the next 12 months. A second tranche of up to $50.0 million remains available under the new credit facility until June 30, 2026. The company anticipates continuing to incur losses as it scales commercialization and advances other product candidates (e.g., rexlemestrocel-L for heart failure and chronic low back pain).

Key Risks and Contingencies:

• Commercialization Execution: Success depends on market acceptance, reimbursement rates, and the ability to scale manufacturing via contract partner Lonza.
• Regulatory & Clinical: Risks include potential adverse events in post-market surveillance of Ryoncil and the success of ongoing trials for other indications.
• Financial Volatility: Significant exposure to fair value remeasurements of warrant liabilities and contingent consideration, which can cause material fluctuations in net loss.
• Debt Covenants: The NovaQuest facility requires repayments based on a percentage of net sales, creating variability in cash outflows.

Investor Verification Checklist

• Ryoncil Sales Velocity: Verify the sustainability of the $48.7 million sales run rate and the impact of gross-to-net adjustments (14.6% of gross revenue).
• Debt Terms: Confirm the specific repayment triggers for the NovaQuest facility and the interest rate (8.00%) on the new credit-line facility.
• Manufacturing Capacity: Assess the capacity of the Lonza manufacturing agreement to meet future demand without supply interruptions.
• Non-Cash Adjustments: Monitor the volatility of warrant liability and contingent consideration remeasurements, which significantly impact reported net loss but not cash flow.
• Cash Burn: Track operating cash burn against the $130 million cash balance to validate the 12-month runway assertion.